INMUNE BIO INC
INMUNE BIO develops immunotherapies and biologics to treat chronic diseases and cancer.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying INMUNE BIO's stock with a target price of $21.5, indicating significant growth potential.
Financial Health
Inmune Bio Inc has very low revenue and modest cash flow, indicating financial difficulties.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring INMB
Pharma's Private Equity Pivot: The Immunology Opportunity
Bristol Myers Squibb has partnered with Bain Capital to launch a new immunology-focused firm, highlighting a trend of pharma giants spinning out assets with private equity backing. This creates an investment opportunity in specialized biotech companies and the broader drug development ecosystem that supports them.
Published: July 29, 2025
Explore BasketMicrobiome Modulators
Discover a carefully selected group of innovative biotechnology companies leveraging the untapped power of the body's microbiome. These pioneering firms are creating revolutionary therapies that target the root causes of disease by rebalancing our internal microbial ecosystems.
Published: June 17, 2025
Explore BasketLottery Tickets
These visionary companies are betting it all on game-changing innovations that could revolutionize entire industries. Hand-selected by our analysts, each represents a high-risk, high-reward opportunity with potential for explosive growth if their breakthrough technologies succeed.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical‑stage focus
Progress depends on trial data and regulatory signals; positive results can change valuation quickly, though outcomes remain uncertain.
Catalysts to watch
Trial readouts, partnership announcements and financing updates can move the share price — monitor official filings and company releases.
Risk and liquidity
Small market cap often means higher volatility and limited liquidity; consider diversification and that this is educational, not personal advice.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals develops treatments for diseases including cystic fibrosis and cancer.
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals is a leading biotechnology company that develops and manufactures innovative medicines for serious medical conditions.
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics based on RNA interference (RNAi).
